HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
HRID 528542Erstellt: 25. Oktober 2026
Potassium Phosphate, Tribasic → N-(4-methoxybenzyl)-4-(2-(1-methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-sulfonamide
https://huagongshe.com/reaction/528542
Beteiligte Stoffe
| Rolle | Name | HCID | Einwaage |
|---|
| Edukt | Potassium Phosphate, Tribasic | HCID 62657 | — |
| Edukt | 1-methyl-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole | HCID 4912908 | — |
| Edukt | 4-(2-chloro-4-(trifluoromethyl)phenyl)-N-(4-methoxybenzyl)-N-(thiazol-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-sulfonamide | HCID 89761797 | — |
| Katalysator | HCID 178482226 | HCID 178482226 | — |
| Produkt | N-(4-methoxybenzyl)-4-(2-(1-methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-sulfonamide | HCID 89762089 | — |
Reaktionsschritte
A 5-mL glass microwave reaction vessel was charged with 4-(2-chloro-4-(trifluoromethyl)phenyl)-N-(4-methoxybenzyl)-N-(thiazol-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-sulfonamide (INTERMEDIATE X, 0.150 g, 0.252 mmol), 1-methyl-1H-pyrazole-5-boronic acid pinacol ester (0.131 g, 0.629 mmol), 1,1-bis[(di-t-butyl-p-methylaminophenyl]palladium(II) chloride (0.027 g, 0.038 mmol), and potassium phosphate (0.083 mL, 1.007 mmol). The vial was sealed and flushed with N2 and dioxane (1 mL) and water (0.32 mL) were added. The mixture was sparged with N2 for 5 min and heated microwave reactor at 112° C. for 3 h. The mixture was diluted with EtOAc and the organic layer was decanted, concentrate and absorbed onto a 5 g loading cartridge and passed through a silica gel column (12 g) using a gradient from 0% to 80% EtOAc in Heptanes to provide N-(4-methoxybenzyl)-4-(2-(1-methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-sulfonamide. This product was dissolved in DCM (1 mL), cooled to 0° C., and trifluoroacetic acid was added (0.5 mL) dropwise. The solution was maintained at rt for 15 min, then concentrated to dryness. The residue was taken up in DCM and passed through an SCX column (10 g column), flushing with DCM. The product was released by treatment of the SCX column with ammonia (2.0 M) in methanol to afford EXAMPLE 42: 4-(2-(1-methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-sulfonamide (0.030 g, 0.058 mmol). 1H NMR (500 MHz, DMSO-d6) δ ppm 3.66 (s, 2 H) 3.90 (s, 4 H) 4.11 (br. s., 1 H) 6.33 (d, J=1.82 Hz, 1 H) 6.49 (s, 1 H) 6.62-6.73 (m, 1 H) 7.05-7.15 (m, 2 H) 7.43 (d, J=1.82 Hz, 1 H) 7.67 (d, J=8.44 Hz, 1 H) 7.80 (s, 1 H) 7.85 (d, J=8.44 Hz, 1 H).
Herkunft & Nachweise
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patentnummer | US09346798B2 |
|---|
| Quelldatensatz | uspto-grants-2016_05 |
|---|
| ORD ID | ord-1e5c198008b641eb9d419317315e7ef6 |
|---|
| Quellennotiz | uspto-grants-2016_05 |
|---|